FHTX News

Updated Monday, 11/16. US IPO market activity is picking back up ahead of the Thanksgiving holiday, with seven IPOs scheduled to raise $3.6 billion in the week ahead.  Biotech research product provider Maravai LifeSciences (MRVI) plans to raise $1.3 billion at a $6.6 billion market cap. Maravai provides critical products to enable...read more

Five IPOs and 17 SPACs went public this past week. While new filing activity has slowed as the election approaches, four IPOs and four SPACs submitted initial filings. Leading security software provider McAfee (MCFE) priced slightly below the midpoint to raise $740 million at a $9.4 billion market cap. Taken private by Intel in 2011, McAfee provides...read more

Foghorn Therapeutics, a preclinical biotech developing gene therapies for hematologic cancers and solid tumors, raised $120 million by offering 7.5 million shares at $16, within the range of $15 to $17. At pricing, the company commands a fully diluted market value of $628 million. Foghorn is developing a new class of medicines targeting genetically determined dependencies...read more

Foghorn Therapeutics, a preclinical biotech developing gene therapies for hematologic cancers and solid tumors, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $120 million by offering 7.5 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Foghorn Therapeutics would command a fully diluted market value of...read more